<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="brief-report" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">95137</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Short Communication</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Algorithm of antidepressants use in clinical practice</article-title><trans-title-group xml:lang="ru"><trans-title>Алгоритм назначения антидепрессантов в реальной клинической практике</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Putilina</surname><given-names>M. V</given-names></name><name xml:lang="ru"><surname>Путилина</surname><given-names>Марина Викторовна</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, проф. каф. неврологии</p></bio><email>profput@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «РНИМУ им. Н.И.Пирогова»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2018-09-15" publication-format="electronic"><day>15</day><month>09</month><year>2018</year></pub-date><volume>20</volume><issue>9</issue><issue-title xml:lang="en">VOL 20, NO9 (2018)</issue-title><issue-title xml:lang="ru">ТОМ 20, №9 (2018)</issue-title><fpage>101</fpage><lpage>107</lpage><history><date date-type="received" iso-8601-date="2021-12-28"><day>28</day><month>12</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2018, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2018, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/95137">https://consilium.orscience.ru/2075-1753/article/view/95137</self-uri><abstract xml:lang="en"><p>According to the World Health Organization data mixed anxiety and depressive disorder (MADD) and stroke are one of the ten most important healthcare problems. Anxiety symptoms and subsyndromal MADD are found in 76% of the world's population. Depression that internal medicine specialists come across in everyday practice mostly exists in an atypical latent form and is masked with various psychovegetative, algesic and somatic manifestations. Pain syndrome is always combined with various psychopathologic and psychovegetative complaints. The basis therapy includes antidepressant medications that are indicated not only when autonomic disturbances are symptoms of depression but also when they are a part of anxiety and anxiety-phobic disorders even if there is no evident depression.</p></abstract><trans-abstract xml:lang="ru"><p>По данным Всемирной организации здравоохранения, тревожно-депрессивные расстройства (ТДР) и инсульт входят в десятку самых значимых проблем здравоохранения. Симптомы тревоги или субсиндромальные ТДР регистрируются у 76% населения планеты. Депрессия, с которой сталкиваются врачи-интернисты в повседневной практике, чаще всего протекает в скрытой, атипичной форме, маскируясь разнообразными психовегетативными, алгическими, соматическими проявлениями. Болевой синдром всегда сочетается с жалобами психопатологического и психовегетативного характера. Базовыми препаратами терапии являются антидепрессанты. Препараты показаны не только когда вегетативные расстройства являются проявлением депрессии, но и когда они протекают в рамках тревожных и тревожно-фобических расстройств, даже если очевидной депрессии не выявляется.</p></trans-abstract><kwd-group xml:lang="en"><kwd>depression</kwd><kwd>generalized anxiety disorder</kwd><kwd>neuropathic pain</kwd><kwd>antidepressants</kwd><kwd>effectiveness</kwd><kwd>safety</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>депрессия</kwd><kwd>генерализованное тревожное расстройство</kwd><kwd>нейропатическая боль</kwd><kwd>антидепрессанты</kwd><kwd>эффективность</kwd><kwd>безопасность</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>World Health Organization. International statistical classification of disease and relation health problems. 10th ed. Geneva, Switz: World Health Organization, 1992.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Egede L.E. Major depression in individuals with chronic medical disorder: prevalence, correlates and association with health resource utilization, lost productivity and functional disability. General Hospital Psychiatry 2007; 29: 409-16.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Kessler R.C, Berglund P, Dempler O et al. The epidemiology of major depressive disorder: result from the National Comorbidity Survey Replication (NCS-R). J Am Med Assoc 2003; 289: 3095-105.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Вейн А.М., Вознесенская Т.Г., Голубев В.Л. и др. Депрессия в неврологической практике. 3-е изд. М.: МИА, 2007.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Путилина М.В. Тревожно-депрессивные расстройства и инсульт. Возможные этиологические и патогенетические корреляции. Журн. неврологии и психиатрии им. С.С.Корсакова. 2014; 6 (114): 86-93</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>http://www.infoecology.ru/important/statistik</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Kanner A.M. Depression in Neurologic Disorders. Diagnosis and Management, Wiley-Black Well, 2012.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Лаукс Г., Мюллер Х. Психиатрия и психотерапия. Справочник. Пер. с нем. М.: МЕДпресс-информ, 2010.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Mitchell J, Trangle M, Degnan B et al. Institute for Clinical Systems Improvement. Adult Depression in Primary Care. 2013. Available at: https://www.icsi.org/_asset/fnhdm3/Depr-Interactive0512b.pdf.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Вознесенская Т.Г. Депрессия при цереброваскулярных заболеваниях. Неврология, нейропсихиатрия и психосоматика. 2009, 2: 9-13. https://doi.org/10.14412/2074-2711-2009-</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Руководство по психиатрии. Под ред. А.С.Тиганова. М.: Медицина, 2012.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Depression and Other Common Mental Disorders: Global Health Estimates. Geneva: World Health Organization, 2017.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>D'Amato C, Morganti R, Greco C et al. Diabetic peripheral neuropathic pain is a stronger predictor of depression than other diabetic complications and comorbidities. Diab Vasc Dis Res 2016; 13 (6): 418-28.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Taylor W.D, Aizenstein H.J, Alexopoulos G.S. The vascular depression hypothesis: mechanisms linking vascular disease with depression. Mol Psychiatry 2013; 18 (9): 963-74. DOI: 10.1038/mp.2013.20</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Breslau N, Lipton R.B, Stewart W.F. Comorbidity of pain and depression: investigation potential etiology and prognosis. Neurology 2003; 60: 1308-12.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Bruti G, Magnotti M.C, Iannetti G. Migraine and depression: bidirectional co-morbidities? Neurol Sci 2012; 33 (Suppl. 1): 107. https://doi.org/10.1007/s10072-012-1053-6</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Rudy T.E, Kerns R.D, Turk D.C. Chronic pain and depression: towards a cognitive behavioral medication model. Pain 2012, 35: 129-40. DOI: 10.1016/0304-3959(88)90220-5</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Крупаткин А.И., Кулешов А.А., Соколова Т.В., Господ А.О. Патопсихологические аспекты болевых синдромов в нижней части спины. Журн. неврологии и психиатрии им. С.С.Корсакова. 2017; 117 (4): 102-6. DOI: 10.17116/jnevro201711741102-106</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Кузюкова А.А., Рачин А.П. Панические атаки в неврологической практике. РМЖ. 2017; 13: 986-91. https://www.rmj.ru/articles/nevrologiya/Panicheskie_ataki_v_nevrologicheskoy_praktike_3/#ixzz5OXoG3J]</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Смулевич А.Б., Колюцкая Е.В. Невротические и личностные расстройства. Психиатрия. Т. 2. Руководство для врачей. Под ред. А.С.Тиганова. М.: Медицина, 2012.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Караваева Т.А., Васильева А.А., Полторак С.В. и др. Критерии и алгоритм диагностики тревожно-фобических расстройств. Обозрение психиатрии и мед. психологии им. В.М.Бехтерева. 2015; 4: 117-23.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Панические расстройства. Клинические рекомендации. Проект (версия 14.02.2018). Российское общество психиатров. psychiatr.ru</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Баринов А.Н., Ахмеджанова Л.Т., Махинов К.А. Алгоритмы диагностики и лечения невропатической боли при поражении периферической нервной системы. РМЖ. 2016; 3: 154-62.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Быков Ю.Н., Калягин А.Н. Дифференциальная диагностика невропатической боли. Неврология, нейропсихиатрия, психосоматика. 2015; 1: 4-10</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Бородулина И.В., Рачин А.П. Полинейропатии в практике врача: особенности патогенеза, клиники и современные подходы к лечению болевых и безболевых форм. РМЖ. 2016; 25: 1705-10</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Higgins J.P.T, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration 2011. Available from: handbook.cochrane.org</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Spallone V, Lacerenza M, Rossi A. Painful Diabetic Polyneuropathy: Approach to Diagnosis and Management. Clin J Pain 2012; 28 (8): 726-43. DOI: 10.1097/AJP.0b013e318243075c</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Russo S.J, Charney D.S. Next generation antidepressants. PNAS 2013; 110 (12): 4441-2. https://doi.org/10.1073/pnas.1301593110</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Руководство по первичной медико-санитарной помощи. М.: ГЭОТАР, 2006.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Приказ МЗ РФ от 20 декабря 2012 г. No1219н «Об утверждении стандарта первичной медико-санитарной помощи при депрессиях легкой и средней степени тяжести и смешанном тревожном и депрессивном расстройстве в амбулаторных условиях психоневрологического диспансера». http://www.rosminzdrav.ru/documents/8517-prikaz-ministerstva-zdravoohraneniya-rossiyskoy-federatsii-..</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Thase М.Е. Antidepressant treatment of the depressed patient with insomnia. J Clin Psychiatry 1999; 60 (Suppl. 17): 28-31; discussion 46-8. https://www.ncbi.nlm.nih.gov/pubmed/10446739#</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Cipriani A et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373 (9665): 746-58.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Eiji Kirino. Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability. Patient Prefer Adherence 2012; 6: 853-61.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Инструкция по применению лекарственного препарата Эсцитaлопрам.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Lepola U, Wade A, Andersen H.F. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 2004; 19: 149-55.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Montgomery S.A, Lader M, Burger V et al. Escitalopram and paroxetine in fixed doses for the treatment of social anxiety disorder (SAD). Nord J Psychiat 2003; 57: 103.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Montgomery S.A, Huusom A.K.T, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004; 50: 57-64.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Crocco E.A, Jaramillo S, Cruz-Ortiz C. Pharmacological Management of Anxiety Disorders in the Elderly. Curr Treat Options Psych 2017; 4: 33. https://doi.org/10.1007/s40501-017-0102-4</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Bird S.T, Crentsil V, Temple R et al. Cardiac safety concerns remain for citalopram at dosages above 40 mg/day. Am J Psychiatr 2014; 171: 17-9. https://doi.org/10.1176/ appi.ajp.2013.13070905</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Tully P.J, Harrison N.J, Cheung P, Cosh S. Anxiety and cardiovascular disease risk: a review. Curr Cardiol Rep 2016. DOI: 10.1007/s11886-016-0800-3</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Государственный реестр лекарственных средств. http://grls.rosminzdrav.ru 29.10.2017. 2.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Инструкция по применению лекарственного препарата Элицея® Ку-таб®.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Wade A.G, Crawford G.M, Young D. A survey of patient preferences for a placebo orodispersible tablet. Patient Preference and Adherence 2012; 6: 201-6. 3.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Богданов Э.И., Саковец Т.Г. Особенности этиологии, патогенеза и клинических проявлений болевых нейропатий. Неврол. вестн. 2014; 3: 28-34.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Рекомендации по медикаментозному лечению нейропатической боли, 2017http://www.medznat.ru/ru/node/4116</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Qaseem A, Wilt T.J, McLean R.M, Forciea M.A. Clinical Guidelines Committee of the American College of Physicians. Noninvasive Treatments for Acute, Subacute, and Chronic Low Back Pain: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med 2017; 166 (7): 514-30.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Able S.L, Cui Z, Shen W. Duloxetine treatment adherence across mental health andchronic pain conditions. Clinicoecon Outcomes Res 2014; 6: 75-81. DOI: 10.2147/CEOR.S52950. eCollection 2014</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Hughes L.M, Wiffen R.A. Philip Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. J Cochrane Database Syst Rev 2014; 1: 2.</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Fitzcharles M.A, Ste-Marie P.A, Goldenberg D.L et al. 2012 Canadian guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary. Pain Res Manag 2013; 18 (3): 119-26. http://dx.doi.org/10.1155/2013/918216</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Radovanovič M, Pišljar M, Barbič-Žagar B et al. Efficacy and Safety of Duloxetine in the Treatment of Depression, Generalized Anxiety Disorder and Diabetic Peripheral Neuropathic Pain. Viceversa 2017; 63: 60-72.</mixed-citation></ref></ref-list></back></article>
